

### What patents are most relevant to the ongoing ANDA litigation?

Amarin has numerous patents listed in the Orange book. They can be found using this link [https://www.accessdata.fda.gov/scripts/cder/ob/patent\\_info.cfm?Product\\_No=001&Appl\\_No=202057&Appl\\_type=N](https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=202057&Appl_type=N).

The patents below were asserted in the initial complaint with respect to currently ongoing ANDA litigation:

- U.S. Patent No. 8,293,728
- U.S. Patent No. 8,318,715
- U.S. Patent No. 8,357,677
- U.S. Patent No. 8,367,652
- U.S. Patent No. 8,377,920
- U.S. Patent No. 8,399,446
- U.S. Patent No. 8,415,335
- U.S. Patent No. 8,426,399
- U.S. Patent No. 8,431,560
- U.S. Patent No. 8,440,650
- U.S. Patent No. 8,518,929
- U.S. Patent No. 8,524,698
- U.S. Patent No. 8,546,372
- U.S. Patent No. 8,617,594

As is generally preferred by the court system and customary in patent litigation, the number of patents and associated claims will likely be truncated so that only a negotiated subset of these patents and related claims would be litigated at trial.

Each of the above listed patents pertain to the current label for *Vascepa*®. Amarin has multiple granted patents and pending patent applications which pertain to the use of *Vascepa* for cardiovascular risk reduction. After *Vascepa*'s label is expanded to reflect the use of *Vascepa* for cardiovascular risk reduction, it is Amarin's intention to add applicable patents to the Orange Book. Below are granted U.S. patents pertaining to use of *Vascepa* for cardiovascular risk reduction (as of October 16, 2019):

- 1) 9,603,826
- 2) 9,610,272
- 3) 9,623,001
- 4) 9,693,985
- 5) 9,693,984
- 6) 9,693,986
- 7) 9,918,954
- 8) 10,278,935
- 9) 10,278,936
- 10) 10,278,937
- 11) 10,383,840
- 12) 10,406,130

Information regarding ongoing ANDA litigation is available via court filings at PACER:  
<https://www.pacer.gov/>

Dated October 22, 2019